168 related articles for article (PubMed ID: 15939802)
1. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment.
Ward RJ; Autexier C
Mol Pharmacol; 2005 Sep; 68(3):779-86. PubMed ID: 15939802
[TBL] [Abstract][Full Text] [Related]
2. Consequences of telomerase inhibition by BIBR1532 on proliferation and chemosensitivity of chondrosarcoma cell lines.
Parsch D; Brassat U; Brümmendorf TH; Fellenberg J
Cancer Invest; 2008 Jul; 26(6):590-6. PubMed ID: 18584350
[TBL] [Abstract][Full Text] [Related]
3. Telomerase inhibition and telomere targeting in hematopoietic cancer cell lines with small non-nucleosidic synthetic compounds (BIBR1532).
El Daly H; Martens UM
Methods Mol Biol; 2007; 405():47-60. PubMed ID: 18369817
[TBL] [Abstract][Full Text] [Related]
4. Targeted inhibition of telomerase activity combined with chemotherapy demonstrates synergy in eliminating ovarian cancer spheroid-forming cells.
Meng E; Taylor B; Ray A; Shevde LA; Rocconi RP
Gynecol Oncol; 2012 Mar; 124(3):598-605. PubMed ID: 22115853
[TBL] [Abstract][Full Text] [Related]
5. Resistance to telomerase inhibition by human squamous cell carcinoma cell lines.
Bojovic B; Crowe DL
Int J Oncol; 2011 Apr; 38(4):1175-81. PubMed ID: 21305252
[TBL] [Abstract][Full Text] [Related]
6. Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells.
Gomez-Millan J; Goldblatt EM; Gryaznov SM; Mendonca MS; Herbert BS
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):897-905. PubMed ID: 17175117
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents.
Cookson JC; Dai F; Smith V; Heald RA; Laughton CA; Stevens MF; Burger AM
Mol Pharmacol; 2005 Dec; 68(6):1551-8. PubMed ID: 16150933
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of human telomerase enhances the effect of chemotherapeutic agents in lung cancer cells.
Misawa M; Tauchi T; Sashida G; Nakajima A; Abe K; Ohyashiki JH; Ohyashiki K
Int J Oncol; 2002 Nov; 21(5):1087-92. PubMed ID: 12370759
[TBL] [Abstract][Full Text] [Related]
9. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells.
Chen Z; Koeneman KS; Corey DR
Cancer Res; 2003 Sep; 63(18):5917-25. PubMed ID: 14522918
[TBL] [Abstract][Full Text] [Related]
10. Mutated telomeres sensitize tumor cells to anticancer drugs independently of telomere shortening and mechanisms of telomere maintenance.
Cerone MA; Londoño-Vallejo JA; Autexier C
Oncogene; 2006 Nov; 25(56):7411-20. PubMed ID: 16767163
[TBL] [Abstract][Full Text] [Related]
11. A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines.
Shi Y; Sun L; Chen G; Zheng D; Li L; Wei W
Target Oncol; 2015 Dec; 10(4):565-73. PubMed ID: 25916999
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease.
Tárkányi I; Aradi J
Biochimie; 2008 Jan; 90(1):156-72. PubMed ID: 17945408
[TBL] [Abstract][Full Text] [Related]
13. Can inhibition of telomerase increase pancreatic cancer cell's susceptibility to chemotherapeutic reagents?
Teng LS; Fahey TJ
Hepatobiliary Pancreat Dis Int; 2002 Feb; 1(1):155-60. PubMed ID: 14607648
[TBL] [Abstract][Full Text] [Related]
14. Oligonucleotide N3'-->P5' phosphoramidates as efficient telomerase inhibitors.
Herbert BS; Pongracz K; Shay JW; Gryaznov SM
Oncogene; 2002 Jan; 21(4):638-42. PubMed ID: 11850790
[TBL] [Abstract][Full Text] [Related]
15. Telomere length mediates the effects of telomerase on the cellular response to genotoxic stress.
Rubio MA; Davalos AR; Campisi J
Exp Cell Res; 2004 Aug; 298(1):17-27. PubMed ID: 15242758
[TBL] [Abstract][Full Text] [Related]
16. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer.
Hochreiter AE; Xiao H; Goldblatt EM; Gryaznov SM; Miller KD; Badve S; Sledge GW; Herbert BS
Clin Cancer Res; 2006 May; 12(10):3184-92. PubMed ID: 16707619
[TBL] [Abstract][Full Text] [Related]
17. Suppression of telomerase activity as an indicator of drug-induced cytotoxicity against cancer cells: in vitro studies with fresh human tumor samples.
Faraoni I; Graziani G; Turriziani M; Masci G; Mezzetti M; Testori A; Veronesi U; Bonmassar E
Lab Invest; 1999 Aug; 79(8):993-1005. PubMed ID: 10462037
[TBL] [Abstract][Full Text] [Related]
18. A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia.
Sumi M; Tauchi T; Sashida G; Nakajima A; Gotoh A; Shin-Ya K; Ohyashiki JH; Ohyashiki K
Int J Oncol; 2004 Jun; 24(6):1481-7. PubMed ID: 15138591
[TBL] [Abstract][Full Text] [Related]
19. Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors.
Mueller S; Hartmann U; Mayer F; Balabanov S; Hartmann JT; Brummendorf TH; Bokemeyer C
Invest New Drugs; 2007 Dec; 25(6):519-24. PubMed ID: 17534576
[TBL] [Abstract][Full Text] [Related]
20. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532.
El-Daly H; Kull M; Zimmermann S; Pantic M; Waller CF; Martens UM
Blood; 2005 Feb; 105(4):1742-9. PubMed ID: 15507522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]